APA (7th ed.) Citation

A, E., W, S., T, C., B, B., Y, P., L, C., . . . A, B. (2025). Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. IScience, 28(6), 112752. https://doi.org/10.1016/j.isci.2025.112752

Chicago Style (17th ed.) Citation

A, Emanuelli, et al. "Targeting the IL34-CSF1R Axis Improves Metastatic Renal Cell Carcinoma Therapy Outcome via Immune-vascular Crosstalk Regulation." IScience 28, no. 6 (2025): 112752. https://doi.org/10.1016/j.isci.2025.112752.

MLA (9th ed.) Citation

A, Emanuelli, et al. "Targeting the IL34-CSF1R Axis Improves Metastatic Renal Cell Carcinoma Therapy Outcome via Immune-vascular Crosstalk Regulation." IScience, vol. 28, no. 6, 2025, p. 112752, https://doi.org/10.1016/j.isci.2025.112752.